U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07425600) titled 'Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass' on Feb. 09.
Brief Summary: Heart surgery is essential for many cardiovascular conditions, but it is a major operation with a significant mortality rate of around 4% in Europe. Among the main complications encountered postoperatively, hemorrhage occurs at a rate of around 8.2% for severe bleeding and 1.6% for massive bleeding.
Hemorrhagic complications are caused by hemostasis disorders attributable to extracorporeal circulation (ECC). Despite recent advances in material design, ECG activates hemostasis, leading to the consumption of various coagulation factors, inc...